Assessment of the Dynamics of Oxidative Stress Indicators and Early Markers of Myocardial Damage and Dysfunction in Patients with Aggressive Lymphoproliferative Diseases During of Anticancer Therapy

Aim      To evaluate the dynamics of indexes of oxidative stress and markers of myocardial injury and dysfunction in patients with aggressive type lymphomas during the antitumor therapy.

Material and methods  This study included 75 patients with lymphoproliferative diseases of aggressive type. The main group consisted of 53 patients who received one course of antitumor therapy during the study. The comparison group consisted of 22 patients who have not received any specific treatment so far. Troponin I (TnI), high-sensitivity troponin (hsTnI), heart-type fatty acid binding protein (Н-FAВР), N-terminal pro-brain natriuretic peptide (NT-prоBNP), superoxide dismutase (SOD), and myeloperoxidase (MPO) were measured in patients of both groups at baseline, and in the main group, they were measured at 4 hours after administration of antitumor agents and on completion of the course. Functional status of the cardiovascular system was evaluated by electrocardiography in all patients at baseline and after the course of antitumor treatment and by echocardiography.

Results The chemotherapy was associated with increased levels of NT-prоBNP, SOD, and MPO (30.670±15.367 vs. 52.309±25.718 pmo l/l; 1.61±0.135 vs. 1.74±0.193 U/ml; and 507.54±91.51 vs. 742.3±49.01 ng/ml, respectively). The study results indicated activation of oxidative stress on the background of the administered antitumor therapy, progressive myocardial dysfunction, and increased frequency of arrhythmic episodes.

Conclusion      The study results allowed identifying NT-prоBNP, MPO, and SOD as important indexes for determining a patient group at high risk of cardiotoxicity during the antitumor treatment.

1. Abe J, Sood AK, Martin JF. Editorial: Cardio-Oncology: From Bench to Bedside. Frontiers in Cardiovascular Medicine. 2019;6:37. DOI: 10.3389/fcvm.2019.00037

2. Snipelisky D, Park JY, Lerman A, Mulvagh S, Lin G, Pereira N et al. How to Develop a Cardio-Oncology Clinic. Heart Failure Clinics. 2017;13(2):347–59. DOI: 10.1016/j.hfc.2016.12.011

3. Harrison’s principles of internal medicine. Chapter 104. P. 769-781. Jameson JL, editor -New York: McGraw-Hill Education;2018. - 1904 p. ISBN 978-1-259-64404-7

4. Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204. DOI: 10.1136/bmj.k3204

5. Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochimica Et Biophysica Acta. 1988;961(1):148–52. DOI: 10.1016/0005-2760(88)90141-5

6. Kalinichenko R.M., Kopylov F.Yu. Perspectives of heart-type fatty acid binding protein application in diagnostics of myocardial infarction. Cardiology and Cardiovascular Surgery. 2012;5(3):13–7.

7. Hoffmann U, Espeter F, Weiß C, Ahmad-Nejad P, Lang S, Brueckmann M et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovascular Disorders. 2015;15(1):50. DOI: 10.1186/s12872-015-0026-0

8. Okamoto F, Sohmiya K, Ohkaru Y, Kawamura K, Asayama K, Kimura H et al. Human Heart-Type Cytoplasmic Fatty Acid-Binding Protein (H-FABP) for the Diagnosis of Acute Myocardial Infarction. Clinical Evaluation of H-FABP in Comparison with Myoglobin and Creatine Kinase Isoenzyme MB. Clinical Chemistry and Laboratory Medicine. 2000;38(3):231–8. DOI: 10.1515/CCLM.2000.034

9. O’Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP et al. Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. Circulation. 2006;114(6):550–7. DOI: 10.1161/CIRCULATIONAHA.106.641936

10. Matsumoto A, Hirata Y, Momomura S, Suzuki E, Yokoyama I, Sata M et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. American Heart Journal. 1995;129(1):139–45. DOI: 10.1016/0002-8703(95)90054-3

11. Tan L-L, Lyon AR. Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment. Current Treatment Options in Cardiovascular Medicine. 2018;20(7):55. DOI: 10.1007/s11936-018-0641-z

12. Lu X, Zhao Y, Chen C, Han C, Xue L, Xing D et al. BNP as a marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer. Oncology Letters. 2019;18(5):4992–5001. DOI: 10.3892/ol.2019.10827

13. Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma. European Journal of Cancer. 2016;58:112–21. DOI: 10.1016/j.ejca.2016.02.004

14. Ferraro MP, Gimeno‐Vazquez E, Subirana I, Gómez M, Díaz J, Sánchez‐González B et al. Anthracycline‐induced cardiotoxicity in diffuse large B‐cell lymphoma: NT‐proBNP and cardiovascular score for risk stratification. European Journal of Haematology. 2019;102(6):509– 15. DOI: 10.1111/ejh.13234

15. Vasilkova V.M., Pchelin I.Yu., Bayrasheva V.K., Mokhort T.V., Naumenko E.P., Filiptsova N.A. Diagnostic and prognostic values of b-type natriuretic peptides and n-terminal fragment brain natriuretic peptides in patients with type 2 diabetes mellitus and chronic kidney disease. Juvenis Scientia. 2018;2:4–8.

16. Bruno G, Landi A, Barutta F, Ghezzo G, Baldin C, Spadafora L et al. N-Terminal Probrain Natriuretic Peptide Is a Stronger Predictor of Cardiovascular Mortality Than C-Reactive Protein and Albumin Excretion Rate in Elderly Patients With Type 2 Diabetes: The Casale Monferrato population-based study. Diabetes Care. 2013;36(9):2677–82. DOI: 10.2337/dc13-0353

17. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE et al. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. European Heart Journal. 2012;33(18):2272–81. DOI: 10.1093/eurheartj/ehs163

18. Ruleva N.Yu., Zvyagintseva M.A., Dugin S.F. Myeloperoxidase: biological functions and clinical significance. Modern high technology. 2007;8:1–4.

19. Rocca G, Stefano A, Eleuteri E, Anzalone R, Magno F, Corrao S et al. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Research in Cardiology. 2009;104(3):307–20. DOI: 10.1007/s00395-008-0761-9

20. Ikitimur B, Karadag B. Role of myeloperoxidase in cardiology. Future Cardiology. 2010;6(5):693–702. DOI: 10.2217/fca.10.75

21. Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N et al. Use of Myeloperoxidase for Risk Stratification in Acute Heart Failure. Clinical Chemistry. 2010;56(6):944–51. DOI: 10.1373/clinchem.2009.142257

22. Eleuteri E, Di Stefano A, Ricciardolo FL, Magno F, Gnemmi I, Colombo M et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. International Journal of Cardiology. 2009;135(3):386–90. DOI: 10.1016/j.ijcard.2008.11.013

23. Brennan M-L, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ et al. Prognostic Value of Myeloperoxidase in Patients with Chest Pain. New England Journal of Medicine. 2003;349(17):1595– 604. DOI: 10.1056/NEJMoa035003

24. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M et al. A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions. Journal of Biological Chemistry. 2002;277(41):38517–23. DOI: 10.1074/jbc.M205924200

25. Fukai T, Ushio-Fukai M. Superoxide Dismutases: Role in Redox Signaling, Vascular Function, and Diseases. Antioxidants & Redox Signaling. 2011;15(6):1583–606. DOI: 10.1089/ars.2011.3999